Regencell Bioscience: A Binary Biotech Lottery Amid Extreme Speculation and Fundamental Risks
Regencell Bioscience Holdings Ltd. (RGC) is a Cayman Islands-domiciled, early-stage bioscience company with its primary operations based in Hong Kong. The company is singularly focused on the research, development, and prospective commercialization of therapeutics derived from Traditional Chinese Medicine (TCM). Its strategic efforts are directed at addressing neurocognitive disorders and degenerations, with a specific and narrow focus on Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD). As a development-stage entity, Regencell has not yet brought any products to market and, consequently, does not generate any revenue from its core business activities.
The company's primary market segments are patients diagnosed with ADHD and ASD. Its core strategy revolves around the planned launch of three distinct liquid-based, standardized TCM formulae candidates. These candidates are designed to treat mild, moderate, and severe cases of ADHD and ASD. The initial commercialization plan targets the Hong Kong market, with a longer-term ambition to expand into other global markets, most notably the United States, contingent upon securing the necessary and far more stringent regulatory approvals. A secondary, non-core initiative involves a joint venture established with Honor Epic Enterprises Limited, which is expected to explore COVID-19 related treatments within the Asia-Pacific region, though this venture remains pre-commercial.
Regencell Bioscience presents an exceptionally unusual and high-risk investment profile. The company is characterized by a profound and striking disconnect between its multi-billion-dollar market capitalization and its fundamental reality as a pre-revenue, loss-making development company possessing minimal tangible assets. The current valuation appears to be almost entirely divorced from conventional financial metrics and seems to be propelled by speculative market dynamics, a tightly controlled share structure with a very small public float, and a compelling, albeit unproven, narrative. The investment outcome is effectively binary, hinging completely on the long-shot success of its clinical programs in a therapeutic area—neurology—that is historically fraught with exceptionally high rates of failure.
The entire operational and strategic framework of Regencell Bioscience is built upon the potential of its TCM-based therapeutic candidates. The success or failure of these candidates will be the sole determinant of the company's future value.
Regencell's future revenue potential is exclusively contingent upon the successful development and commercialization of its three TCM formulae candidates targeting ADHD and ASD. These formulae are not the product of a large, institutionalized research and development program but are instead based on the proprietary "Sik-Kee Au TCM Brain Theory®". This theory was developed by Mr. Sik-Kee Au, who serves as the company's strategic TCM research partner and is also the father of the company's founder and Chief Executive Officer, Mr. Yat-Gai Au.
The company's pipeline, as disclosed in its public filings, contains no other products or therapeutic candidates. This makes Regencell a pure-play investment on the viability of this specific TCM approach for these two specific neurological indications. There is no diversification within its R&D portfolio to mitigate the risk of failure. The entire enterprise value rests on the hypothesis that this unique, family-derived TCM theory can be translated into a safe, effective, and commercially viable treatment that can pass muster with global health regulators.
Regencell's growth strategy is linear and milestone-dependent, focused on advancing its core assets through clinical and regulatory hurdles before attempting broad commercialization.
The central pillar of the company's strategy is to guide its TCM candidates through the necessary stages of clinical research to secure regulatory approval for commercial sale. The company has completed an initial, small-scale research study in Hong Kong and intends to leverage the data from this study to support further development and future regulatory submissions. The successful navigation of this clinical and regulatory pathway is the single most critical variable for the company's long-term survival and any potential for value creation.
The company has outlined a sequential go-to-market strategy that prioritizes its home market before tackling more complex international territories. The plan is to first launch its products in Hong Kong and, upon achieving success there, to subsequently expand into other markets. In a nod to its global ambitions, Regencell opened an office in California in October 2020. However, the company has been explicit in its filings that it is not actively developing the U.S. market at this time and will only begin preliminary market research once its TCM products obtain regulatory approvals and achieve commercial success in Hong Kong.
This cautious, gated approach to expansion is logical for an early-stage company with limited resources. However, it also underscores the immense regulatory and commercial challenges that lie ahead. The regulatory standards for TCM in Hong Kong may differ significantly from the rigorous, evidence-based requirements of the U.S. Food and Drug Administration (FDA). Therefore, achieving regulatory approval in Hong Kong is not a reliable predictor of success in the U.S. To enter the American market, Regencell would almost certainly be required to conduct new, lengthy, and exceptionally expensive clinical trials designed to meet the FDA's stringent standards. This implies that even a successful launch in Hong Kong represents only an incremental de-risking event, with the far larger and more lucrative U.S. market opportunity remaining a distant, highly uncertain, and capital-intensive prospect. The company's current market capitalization appears to be pricing in global success, not a niche launch in a single city.
In September 2021, Regencell's Hong Kong subsidiary entered into a joint venture agreement with Honor Epic Enterprises Limited. The stated purpose of this JV is to form a new entity to offer COVID-19 related treatments to patients in various Asia-Pacific countries, including ASEAN nations, India, Japan, Australia, and New Zealand. To date, this joint venture has not generated any revenue, and its contribution to the company's financial results has been negligible. For the purposes of this analysis, this JV should be viewed as a non-core, exploratory asset with minimal attributable value in the context of the company's overall investment thesis.
Regencell's competitive positioning is unconventional and rests entirely on its unique approach rather than on traditional industry moats.
The company's primary differentiator is its foundational reliance on Traditional Chinese Medicine in a therapeutic field overwhelmingly dominated by Western pharmaceuticals, such as stimulants (e.g., Adderall, Ritalin) and non-stimulants. If the company's formulae can demonstrate compelling efficacy and a favorable safety profile, this unique approach could become a significant competitive advantage, particularly for patients and families seeking alternative or complementary treatment options.
The strategic partnership with Mr. Sik-Kee Au and his proprietary "TCM Brain Theory®" constitutes the company's core intellectual property. This familial connection provides access to a unique and esoteric knowledge base that cannot be easily replicated by competitors. However, this structure also presents a profound and unquantifiable risk. The company's entire scientific foundation appears to be embodied in a single individual rather than being institutionalized within the company through a diversified R&D team, a robust patent portfolio, or peer-reviewed scientific publications. This creates an extreme form of key-person risk; the company's prospects are inextricably linked to the health, longevity, and continued cooperation of Mr. Sik-Kee Au. This structural vulnerability is a significant departure from the typical R&D models of publicly traded bioscience companies.
At its current stage, Regencell possesses none of the conventional moats that protect established bioscience companies. It lacks a portfolio of issued patents, scaled manufacturing capabilities, an established distribution network, a recognized brand, or significant clinical data published in reputable scientific journals. Its entire competitive position and astronomical market valuation are built upon the unproven promise of its proprietary formulae.
An analysis of Regencell's financial statements reveals a company in the earliest stages of development, with financial metrics that stand in stark contrast to its public market valuation.
Regencell is a pre-revenue company. A review of all public financial disclosures, from its Initial Public Offering (IPO) in July 2021 through its most recent Form 6-K filing for the six-month period ending December 31, 2024, confirms that the company has generated zero revenue from its operations.
The company's financial history is defined by a consistent pattern of operating losses, which are primarily driven by General & Administrative (G&A) and Research & Development (R&D) expenses. The key historical loss figures are as follows:
Fiscal Year 2022 (ended June 30, 2022): Net Loss of $7.59 million.
Fiscal Year 2023 (ended June 30, 2023): Net Loss of $6.06 million.
Fiscal Year 2024 (ended June 30, 2024): Net Loss of $4.30 million.
First Half Fiscal Year 2025 (six months ended December 31, 2024): Net Loss of $1.85 million. This implies an annualized net loss and cash burn rate of approximately $3.7 million, assuming a consistent level of expenditure.
From a balance sheet perspective, as of December 31, 2024, Regencell reported total assets of $7.48 million. This included $6.59 million in current assets, which are predominantly comprised of cash and cash equivalents. Total liabilities were minimal at just $0.76 million, resulting in total shareholders' equity of $6.72 million. This financial position indicates strong near-term liquidity, with sufficient cash to fund operations for approximately 1.5 to 2 years at its current burn rate.
The company's cash burn rate is surprisingly low for a publicly-traded biotechnology firm. While this frugality extends its operational runway without the immediate need to raise additional capital, it is also indicative of the company's very early stage of development. Large, multi-center, late-stage clinical trials, which are necessary for securing regulatory approval in major markets like the U.S., can cost tens or even hundreds of millions of dollars. The low level of R&D spending suggests that the company is very far from generating the kind of pivotal clinical data required for a major regulatory submission. This creates a paradox where the low spending, while preserving cash, also implies that the company's operational tempo and clinical progress are more akin to a private, seed-stage biotech startup than a multi-billion-dollar public entity.
The valuation of Regencell is an extreme outlier when assessed using any conventional financial metric.
Market Capitalization: As of late October 2025, the company's market capitalization is approximately $8.6 billion.
Shares Outstanding: The company has approximately 494.5 million ordinary shares outstanding.
Traditional Multiples: Standard valuation multiples such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Enterprise Value-to-EBITDA (EV/EBITDA) are not applicable (N/A) because the company has no revenue and negative earnings.
Price-to-Book (P/B) Ratio: This is the only applicable traditional valuation multiple, and it is extraordinarily high. Based on a market capitalization of approximately $8.6 billion and shareholders' equity (book value) of $6.72 million, the P/B ratio is approximately 1,280x. This figure starkly illustrates the immense premium that the market is assigning to the company's intangible assets—namely, the unproven potential of its future drug candidates.
The following table provides a concise summary of the company's recent financial history and current valuation, highlighting the disconnect between its operational scale and its market value.
| Metric (USD millions, except per share) | FY 2022 | FY 2023 | FY 2024 | H1 FY2025 (Annualized) |
| Revenue | $0.0 | $0.0 | $0.0 | $0.0 |
| R&D Expense | $2.51 | $1.58 | $1.07 | $1.01 |
| SG&A Expense | $7.01 | $5.50 | $3.99 | $2.93 |
| Net Loss | ($7.59) | ($6.06) | ($4.30) | ($3.71) |
| EPS (Basic) | ($0.0154) | ($0.0119) | ($0.0087) | ($0.0075) |
| Cash & Equivalents (End of Period) | $19.70 | ~$13.64 (est.) | $8.11 | $6.59 |
| Market Cap (as of Oct 2025) | ~$8,600 | |||
| Price/Book Ratio | ~1,280x | |||
Sources: | ||||
| Note: FY 2023 Cash is estimated based on FY2022 ending cash and FY2023 net loss. |
Investing in Regencell Bioscience involves an exceptionally high degree of risk, spanning clinical, financial, and corporate governance domains. These risks are magnified by the stock's speculative nature and extreme valuation.
Clinical and Regulatory Failure: This is the most significant and probable risk facing the company. The field of neurology is notorious for its high clinical trial failure rates. Data from the biopharmaceutical industry shows that only approximately 5.9% of neurology drugs that enter Phase 1 clinical trials ultimately gain FDA approval, implying a failure rate of over 94%. Regencell faces an additional layer of regulatory risk because its therapeutic candidates are based on TCM. Demonstrating safety and efficacy for a complex, multi-component TCM formula to the satisfaction of regulators like the FDA, which are accustomed to evaluating single-molecule new chemical entities, presents a formidable and unprecedented challenge.
Valuation and Speculative Risk: The company's stock price is fundamentally untethered from its current financial condition or operational progress. This makes it highly susceptible to sudden and dramatic shifts in market sentiment. The company itself acknowledges this risk in its public filings, warning that a "short squeeze has led and could continue to lead to volatile price movements" that are unrelated to its operating performance. This volatility is exacerbated by the company's share structure, which features a very small public float of approximately 19 million shares out of a total of 494.5 million shares outstanding. This thin float means that relatively small trading volumes can trigger disproportionately large price swings, increasing the risk of a rapid valuation collapse.
Concentration and Key Person Risk: The business is entirely dependent on a single, unproven therapeutic platform (TCM for ADHD/ASD). Furthermore, the intellectual foundation of this platform rests with a single individual, Mr. Sik-Kee Au, the CEO's father and strategic TCM partner. This dual concentration creates a fragile business model where a failure in the core scientific hypothesis or the loss of its key practitioner could render the entire enterprise worthless.
Corporate Governance and Control: With CEO Yat-Gai Au beneficially owning approximately 96% of the company's ordinary shares, Regencell qualifies as a "controlled company" under Nasdaq listing standards. This status exempts the company from certain corporate governance requirements, such as the need for a majority-independent board of directors. As a result, minority public shareholders have virtually no influence over corporate strategy, the election of directors, or executive compensation. The interests of the controlling shareholder may not always align with those of minority investors. This concentration of power, combined with the extreme valuation, creates a unique risk profile. A controlling shareholder could theoretically leverage the company's inflated stock for personal benefit (e.g., by pledging shares as collateral for loans) in ways that could introduce new risks for the company and its public shareholders without their consent or recourse.
Commercialization and Competition: In the highly unlikely event that Regencell's products receive regulatory approval, the company would face the monumental challenge of competing against a massive and deeply entrenched pharmaceutical industry. The ADHD and ASD markets are dominated by global giants with well-established drugs, vast sales forces, and enormous marketing budgets. Achieving market acceptance, securing reimbursement from payers, and convincing physicians to prescribe a novel TCM-based formula over established standards of care would be an arduous and costly undertaking.
Capital Markets Environment: As a pre-revenue, cash-burning entity, Regencell will inevitably need to raise substantial additional capital to fund any late-stage clinical trials required for major market approval. A restrictive macroeconomic environment with high interest rates or a general risk-off sentiment in the equity markets could make it significantly more difficult or highly dilutive for the company to secure the necessary funding to advance its pipeline.
Regulatory Scrutiny of Foreign Firms: Regencell is based in Hong Kong and listed on a U.S. exchange. While it is not a mainland Chinese company, it could be subject to broader market sentiment or regulatory changes affecting foreign-listed entities. News reports have indicated that Nasdaq is revamping its listing rules for small IPOs and Chinese firms, which could have unforeseen implications for companies like Regencell in the future.
The following scenario analysis employs a risk-adjusted net present value (rNPV) framework, a standard methodology for valuing pre-revenue biotechnology companies. This approach estimates future potential revenue streams and then heavily discounts them to account for the low probability of clinical and commercial success, as well as the time value of money. The objective is to derive a fundamental value for the company's shares, which can then be compared to the current market price. For the purpose of this analysis, the starting share price is taken as approximately $17.41 as of late October 2025 , and the number of shares outstanding is assumed to be constant at 494.5 million.
The projections are based on the following key inputs derived from market research and industry benchmarks:
Total Addressable Market (TAM): The combined global therapeutics market for ADHD and ASD is projected to be approximately $24 billion by 2030. This is based on a 2023 ADHD market of $15.8 billion growing at a 5.1% compound annual growth rate (CAGR) and a 2025 ASD market of $2.2 billion growing at a 6.5% CAGR.
Probability of Success (PoS): The likelihood of a neurology drug advancing from Phase 1 to FDA approval is approximately 5.9%. Given the additional scientific and regulatory hurdles associated with a novel TCM-based therapy, this analysis will use this industry benchmark as an optimistic ceiling for the probability of success.
Development Timeline: The typical clinical development time for a novel orphan-designated drug is approximately 7.2 years from the start of trials to approval. A 5- to 7-year timeline to potential initial revenue is assumed for modeling purposes.
Pricing: The average annual cost of existing standard-of-care ADHD medication is approximately $1,850 per patient. Novel therapies often command premium pricing. This analysis assumes a potential price point in the range of $2,500 to $5,000 per patient per year.
Operating Expenses: R&D and SG&A expenses are modeled based on historical spending patterns. It is assumed that R&D expenses would need to increase exponentially to fund late-stage trials, necessitating significant future capital raises that would be dilutive to existing shareholders.
Subjective Probability: 75%
Narrative: This scenario reflects the most statistically likely outcome. The company's clinical trials for its ADHD/ASD formulae fail to meet their primary endpoints for efficacy or safety. The results are inconclusive or demonstrate a risk-benefit profile that is unacceptable to regulators. This outcome is consistent with the extremely high historical failure rates for neurological drug candidates. As a result, the company is unable to advance its pipeline, the narrative supporting its speculative valuation evaporates, and investor sentiment collapses.
Financials and Valuation: Revenue remains zero indefinitely. The company continues its cash burn of approximately $4-5 million per year until its cash reserves are depleted. It is unable to raise additional capital due to the clinical failure. The company's valuation reverts to a level reflecting its net tangible assets, which would be minimal.
Projected Share Price (Year 5): Assuming the company's cash depletes to a residual value of approximately $2 million, the market capitalization would contract to this level. A $2 million market cap divided by 494.5 million shares outstanding results in a projected share price of $0.004.
Subjective Probability: 20%
Narrative: In this scenario, the company achieves a measure of early-stage success. It successfully completes a Phase 1 or small Phase 2 trial, likely in Hong Kong, that generates promising but not definitive or registrational-quality data. This positive signal is sufficient to attract a partnership with a larger, established pharmaceutical company that licenses the development and commercialization rights for the therapy outside of Greater China.
Financials and Valuation: Regencell receives a one-time, upfront payment (e.g., $50 million) upon signing the deal, providing a significant infusion of non-dilutive capital. The company also becomes eligible for future milestone payments and a royalty on net sales if the partner successfully develops and commercializes the drug. The valuation is no longer based on pure speculation but on a risk-adjusted NPV of this potential future royalty stream. Assuming the partner could achieve peak annual sales of $500 million (representing less than 2.5% of the 2030 TAM), a standard 10% royalty rate, and a 10% probability of success from this stage forward, the risk-adjusted annual royalty would be $5 million ($500M 10% 10%). Applying a 10x multiple to this mature royalty stream yields a terminal value of $50 million. Adding the upfront payment results in a total risk-adjusted fundamental value for the company of approximately $100 million.
Projected Share Price (Year 5): A market capitalization of $100 million divided by 494.5 million shares outstanding results in a projected share price of $0.20.
Subjective Probability: 5%
Narrative: In this highly optimistic but still constrained scenario, the company defies the overwhelming odds and achieves regulatory approval for its products in Hong Kong and potentially one or two other smaller Asia-Pacific markets. It successfully launches the products and begins to generate its first commercial revenues. However, the pathway to U.S. and European approval remains a distant, expensive, and highly uncertain future objective.
Financials and Valuation: By year five, the company has managed to capture a 1% market share in the Asia-Pacific region (excluding the major markets of Japan and mainland China). Assuming this addressable market represents 15% of the global TAM (approximately $3.6 billion), this translates to $36 million in annual revenue. Profitability remains nascent due to the high SG&A expenses required to build a commercial infrastructure from scratch. The market values the company based on a Price-to-Sales (P/S) multiple. Given the niche nature of the product, the geographic limitations, and the remaining regulatory risks, an optimistic 10x P/S multiple is applied. This results in a projected market capitalization of $360 million (10 * $36M).
Projected Share Price (Year 5): A market capitalization of $360 million divided by 494.5 million shares outstanding results in a projected share price of $0.73.
The table below summarizes the potential 5-year share price trajectory under each fundamentally-driven scenario. It starkly illustrates the significant downside risk from the current price level, even in the most optimistic case.
The probability-weighted 5-year price target is calculated as follows:
This analysis, which is grounded in industry statistics for clinical success and conservative commercial assumptions, suggests a long-term fundamental value that is more than 99% below the current trading price. The market's present valuation is not supported by a rational, probability-weighted assessment of the company's future prospects.
MASSIVELY OVERVALUED
This scorecard provides a systematic assessment of Regencell's qualitative attributes on a scale of 1 (very poor) to 10 (excellent).
| Metric | Score (1-10) | Narrative Rationale |
| Management Alignment | 2 | CEO Yat-Gai Au's beneficial ownership of approximately 96% of the company creates a structure of extreme control, not necessarily alignment with minority public shareholders. As a "controlled company," Regencell is exempt from key Nasdaq governance requirements, such as having a majority of independent directors. This concentration of power means minority investors have no meaningful say in corporate decisions, presenting a significant governance risk. |
| Revenue Quality | 1 | The company is pre-revenue and has never generated any sales from its core operations. There is no revenue to assess, and therefore the quality is non-existent. This score reflects the complete absence of any commercial validation for its products or business model. |
| Market Position | 1 | Regencell has no market position. It is a pre-commercial entity with zero products on the market and zero market share. It aims to enter a highly competitive field dominated by large, well-resourced global pharmaceutical companies with entrenched products and relationships. |
| Growth Outlook | 3 | The theoretical growth potential is immense if the company's lead candidate were to become a successful global therapy. However, this potential is severely diluted by the exceptionally low probability of success. Given the historical ~94% failure rate for neurological drugs in development, the risk-adjusted growth outlook is poor. The score reflects a high-potential, low-probability binary outcome. |
| Financial Health | 4 | The company currently has a clean balance sheet with no debt and sufficient cash to fund its operations for approximately 1.5 to 2 years at its current low burn rate. However, this health is temporary. The company is entirely dependent on future access to capital markets to fund any meaningful late-stage development, which would cost multiples of its current cash balance. |
| Business Viability | 2 | The viability of the entire enterprise rests on a single, unproven scientific hypothesis based on a proprietary TCM theory. The business model is a binary bet on overcoming enormous and sequential clinical, regulatory, and commercial hurdles. The statistical probability of ultimate failure is extremely high. |
| Capital Allocation | 3 | To date, management has been frugal, maintaining a low cash burn rate that preserves capital. However, the company has not yet faced a major strategic capital allocation decision. The very low level of R&D spending, while conserving cash, also suggests a slow development pace that may not be optimal for value creation. |
| Analyst Sentiment | 1 | There is zero formal sell-side analyst coverage from investment banks. This complete lack of institutional research and validation is a significant negative signal. It indicates that the professional investment community largely views the stock as a purely speculative instrument rather than a fundamentally sound investment. |
| Profitability | 1 | The company has a consistent history of generating net losses since its inception and has no clear path or timeline to profitability. Profitability is a distant and highly uncertain prospect that would only be possible after many years of further investment and successful commercialization. |
| Track Record | 1 | As a company that went public in July 2021, Regencell has a very limited operating history as a public entity and no track record of creating shareholder value through fundamental business execution. The extraordinary appreciation in its stock price has been driven by speculative market dynamics, not by the achievement of any significant clinical or commercial milestones. |
| Overall Blended Score | 1.9 / 10 |
HIGHLY SPECULATIVE
Regencell Bioscience stands as one of the most extreme examples of a valuation disconnect observable in the public markets. It is a pre-revenue, clinical-stage company founded on a speculative and unproven therapeutic platform, yet it commands a multi-billion-dollar market capitalization that is typically associated with companies possessing late-stage clinical assets or established revenue streams. Our fundamental analysis, based on conservative commercial assumptions and industry-standard probabilities of success for neurological drug development, indicates a fair value for the company's shares that is over 99% lower than its current trading price. The investment proposition is therefore not grounded in a rational assessment of future discounted cash flows.
The primary drivers of the stock price are likely to remain sentiment-based rather than fundamental. Potential positive catalysts would include press releases announcing the initiation of new clinical trials, the publication of any early-stage data (regardless of its statistical rigor), or news of a potential partnership. Such events could fuel further speculative buying from the retail investor community. Conversely, the key negative catalysts are a clinical trial failure, a significant and dilutive capital raise, or a broader shift in retail investor sentiment away from speculative assets. Any of these events could trigger a catastrophic and rapid price collapse.
The investment thesis for Regencell Bioscience is not based on fundamentals but is a pure speculation on market structure and crowd psychology. The combination of a low public float and highly concentrated insider control creates a fertile environment where a stock's price can be driven to, and sustained at, irrational levels for extended periods. An investor in RGC is not purchasing a claim on a probable stream of future earnings; they are purchasing a lottery ticket with two conditions for success: first, a highly improbable clinical and regulatory victory, and second, the continuation of a speculative bubble. Given the overwhelming odds against its scientific platform and the profound disconnect from any measure of fundamental value, the risk of a near-complete and permanent loss of capital is exceptionally high.
FUNDAMENTALLY UNTETHERED
As of late 2025, Regencell's stock is trading significantly above its 200-day moving average, which various sources place between $8.31 and $16.10. This technically indicates a long-term uptrend. However, this simple indicator belies the underlying nature of the price action, which is defined by extreme and violent volatility. The stock's 52-week range has spanned from a low of $0.09 to a high of over $83, demonstrating that it is not in a stable trend but is subject to massive, sentiment-driven swings. Recent price appreciation has been fueled by events like a 1-for-38 forward stock split in June 2025, which increases share liquidity and can attract retail interest, rather than any substantive clinical or financial news. The short-term outlook is therefore unpredictable and will be dictated entirely by news flow and market sentiment, not by underlying business fundamentals.
SENTIMENT DRIVEN
View Regencell Bioscience Holdings Ltd (RGC) stock page
Loading the interactive version of this report…